Tome Biosciences is the programmable gene insertion company. Using CRISPR, our technologies allow us to insert any genetic sequence of any size at any location into any genome. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and genome engineering.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $213M
Investors 1
| Date | Name | Website |
| 26.03.2022 | ARCH Ventu... | archventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2023 | Series A | $213M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 18.12.2023 | Tome Biosciences: Programmable Genomic Integration Company R... | Tome Biosciences – a programmable genomic integration company – recently announced it has launched t... | pulse2.com... |
| 13.12.2023 | Tome Biosciences Raises Over $213M in Series A and Series B | Tome Biosciences, Inc., a Watertown, MA-based programmable genomic integration company, raised $213m... | finsmes.co... |
| 12.12.2023 | Tome Biosciences Launches with Over $200 Million in Funding ... | - | globenewsw... |